Proteolytic processing of Von Willebrand Factor by Adamts13 and Leukocyte Proteases

Mediterranean Journal of Hematology and Infectious Diseases

Volumn 5, Issue 1, 2013, Pages

  Lancellotti, Stefano ^a   Basso, Maria ^a   De Cristofaro, Raimondo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LEUKOCYTE PROTEINASE; SERINE PROTEINASE; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADAMTS13 GENE; ARTERY THROMBOSIS; DISEASE ASSOCIATION; GENE MUTATION; HEMOLYTIC UREMIC SYNDROME; HERITABILITY; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; PATHOGENESIS; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 84908240216     PISSN: None     EISSN: 20353006     Source Type: Journal    
DOI: 10.4084/mjhid.2013.058     Document Type: Review

References (137)

1. Moake JL, Rudy CK, Troll JH, Weinstein MJ, Colannino NM, Azocar J, Seder RH, Hong SL, Deykin D. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med. 1982; 307: 1432-5. http://dx.doi.org/10.1056/NEJM198212023072306 PMid:6813740
2. Furlan M, Robles R, Lamie B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood. 1996; 87: 4223-34. PMid:8639781
3. Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood. 1996; 87: 4235-44. PMid:8639782
4. Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood. 2001; 98: 1662-6. http://dx.doi.org/10.1182/blood. V98.6.1662 PMid:11535495
5. Gerritsen HE, Robles R, Lammle B, Furlan M. Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood. 2001; 98: 1654-61. http://dx.doi.org/10.1182/blood. V98.6.1654 PMid:11535494
6. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, Yang AY, Siemieniak DR, Stark KR, Gruppo R, Sarode R, Shurin SB, Chandrasekaran V, Stabler SP, Sabio H, Bouhassira EE, Upshaw JD, Jr., Ginsburg D, Tsai HM. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001; 413: 488-94. http://dx.doi.org/10.1038/35097008 PMid:11586351
7. Soejima K, Mimura N, Hirashima M, Maeda H, Hamamoto T, Nakagaki T, Nozaki C. A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease? J Biochem. 2001; 130: 475-80. http://dx.doi.org/10.1093/oxfordjournals.jbchem.a003009 PMid:11574066
8. Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem. 2001; 276: 41059-63. http://dx.doi.org/10.1074/jbc. C100515200 PMid:11557746
9. Tsai HM. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. J Mol Med. 2002; 80: 639-47. http://dx.doi.org/10.1007/s00109-002-0369-8 PMid:12395148
10. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 1998; 67: 395-424. http://dx.doi.org/10.1146/annurev.biochem.67.1.395 PMid:9759493
11. Wagner DD, Marder VJ. Biosynthesis of von Willebrand protein by human endothelial cells. Identification of a large precursor polypeptide chain. J Biol Chem. 1983; 258: 2065-7. PMid:6600453
12. Ruggeri ZM, Zimmerman TS. The complex multimeric composition of factor VIII/von Willebrand factor. Blood. 1981; 57: 1140-3. PMid:6784794
13. Tsai HM, Nagel RL, Hatcher VB, Sussman, II. Multimeric composition of endothelial cell-derived von Willebrand factor. Blood. 1989; 73: 2074-6. PMid:2786433
14. Padilla A, Moake JL, Bernardo A, Ball C, Wang Y, Arya M, Nolasco L, Turner N, Berndt MC, Anvari B, Lopez JA, Dong JF. P-selectin anchors newly released ultralarge von Willebrand factor multimers to the endothelial cell surface. Blood. 2004; 103: 2150-6. http://dx.doi.org/10.1182/blood-2003-08-2956 PMid:14630802
15. Sadler JE. von Willebrand factor. J Biol Chem. 1991; 266: 22777-80. PMid:1744071
16. Scaglione GL, Lancellotti S, Pap M, De Spirito M, Maiorana A, Baronciani L, Pagliari MT, Arcovito A, Di Stasio E, Peyvandi F, De Cristofaro R. The Type 2b P.R1306w Natural Mutation Of Von Willebrand Factor Dramatically Enhances The Multimer Sensitivity To Shear Stress. J Thromb Haemost. 2013. http://dx.doi.org/10.1111/jth.12346
17. Tsai HM, Sussman, II, Nagel RL. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. Blood. 1994; 83: 2171-9. PMid:8161783
18. Di Stasio E, Romitelli F, Lancellotti S, Arcovito A, Giardina B, De Cristofaro R. Kinetic study of von Willebrand factor self-aggregation induced by ristocetin. Biophys Chem. 2009; 144: 101-7. http://dx.doi.org/10.1016/j.bpc.2009.07.002 PMid:19647361
19. Di Stasio E, De Cristofaro R. The effect of shear stress on protein conformation: Physical forces operating on biochemical systems: The case of von Willebrand factor. Biophys Chem. 2010; 153: 1-8. http://dx.doi.org/10.1016/j.bpc.2010.07.002 PMid:20797815
20. Lopez JA, Dong JF. Cleavage of von Willebrand factor by ADAMTS-13 on endothelial cells. Semin Hematol. 2004; 41: 15-23. http://dx.doi.org/10.1053/j.seminhematol.2003.10.004
21. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lammle B. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998; 339: 1578-84. http://dx.doi.org/10.1056/NEJM199811263392202 PMid:9828245
22. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998; 339: 1585-94. http://dx.doi.org/10.1056/NEJM199811263392203 PMid:9828246 PMCid:PMC3159001
23. Hulstein JJ, de Groot PG, Silence K, Veyradier A, Fijnheer R, Lenting PJ. A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B. Blood. 2005; 106: 3035-42. http://dx.doi.org/10.1182/blood-2005-03-1153 PMid:16014562
24. Chung DW, Fujikawa K. Processing of von Willebrand factor by ADAMTS-13. Biochemistry. 2002; 41: 11065-70. http://dx.doi.org/10.1021/bi0204692
25. Plaimauer B, Zimmermann K, Volkel D, Antoine G, Kerschbaumer R, Jenab P, Furlan M, Gerritsen H, Lammle B, Schwarz HP, Scheiflinger F. Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood. 2002; 100: 3626-32. http://dx.doi.org/10.1182/blood-2002-05-1397 PMid:12393399
26. Kokame K, Matsumoto M, Soejima K, Yagi H, Ishizashi H, Funato M, Tamai H, Konno M, Kamide K, Kawano Y, Miyata T, Fujimura Y. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci U S A. 2002; 99: 11902-7. http://dx.doi.org/10.1073/pnas.172277399 PMid:12181489 PMCid:PMC129366
27. Shang D, Zheng XW, Niiya M, Zheng XL. Apical sorting of ADAMTS13 in vascular endothelial cells and Madin-Darby canine kidney cells depends on the CUB domains and their association with lipid rafts. Blood. 2006; 108: 2207-15. http://dx.doi.org/10.1182/blood-2006-02-002139 PMid:16597588 PMCid:PMC1895558
28. Turner N, Nolasco L, Tao Z, Dong JF, Moake J. Human endothelial cells synthesize and release ADAMTS-13. J Thromb Haemost. 2006; 4: 1396-404. http://dx.doi.org/10.1111/j.1538-7836.2006.01959.x PMid:16706987
29. Tati R, Kristoffersson AC, Stahl AL, Morgelin M, Motto D, Satchell S, Mathieson P, Manea-Hedstrom M, Karpman D. Phenotypic expression of ADAMTS13 in glomerular endothelial cells. PLoS One. 2011; 6: e21587. http://dx.doi.org/10.1371/journal.pone.0021587 PMid:21720563 PMCid:PMC3123364
30. Liu L, Choi H, Bernardo A, Bergeron AL, Nolasco L, Ruan C, Moake JL, Dong JF. Platelet-derived VWF-cleaving metalloprotease ADAMTS-13. J Thromb Haemost. 2005; 3: 2536-44. http://dx.doi.org/10.1111/j.1538-7836.2005.01561.x PMid:16176307
31. Suzuki M, Murata M, Matsubara Y, Uchida T, Ishihara H, Shibano T, Ashida S, Soejima K, Okada Y, Ikeda Y. Detection of von Willebrand factor-cleaving protease (ADAMTS-13) in human platelets. Biochem Biophys Res Commun. 2004; 313: 212-6. http://dx.doi.org/10.1016/j.bbrc.2003.11.111 PMid:14672719
32. Soejima K, Nakamura H, Hirashima M, Morikawa W, Nozaki C, Nakagaki T. Analysis on the molecular species and concentration of circulating ADAMTS13 in Blood. J Biochem. 2006; 139: 147-54. http://dx.doi.org/10.1093/jb/mvj013 PMid:16428330
33. Crawley JT, de Groot R, Xiang Y, Luken BM, Lane DA. Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor. Blood. 2011; 118: 3212-21. http://dx.doi.org/10.1182/blood-2011-02-306597 PMid:21715306 PMCid:PMC3179391
34. Ono T, Mimuro J, Madoiwa S, Soejima K, Kashiwakura Y, Ishiwata A, Takano K, Ohmori T, Sakata Y. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood. 2006; 107: 528-34. http://dx.doi.org/10.1182/blood-2005-03-1087 PMid:16189276
35. Uemura M, Tatsumi K, Matsumoto M, Fujimoto M, Matsuyama T, Ishikawa M, Iwamoto TA, Mori T, Wanaka A, Fukui H, Fujimura Y. Localization of ADAMTS13 to the stellate cells of human liver. Blood. 2005; 106: 922-4. http://dx.doi.org/10.1182/blood-2005-01-0152 PMid:15855280
36. Zhou W, Inada M, Lee TP, Benten D, Lyubsky S, Bouhassira EE, Gupta S, Tsai HM. ADAMTS13 is expressed in hepatic stellate cells. Lab Invest. 2005; 85: 780-8. http://dx.doi.org/10.1038/labinvest.3700275 PMid:15806136 PMCid:PMC2573995
37. Niiya M, Uemura M, Zheng XW, Pollak ES, Dockal M, Scheiflinger F, Wells RG, Zheng XL. Increased ADAMTS-13 proteolytic activity in rat hepatic stellate cells upon activation in vitro and in vivo. J Thromb Haemost. 2006; 4: 1063-70. http://dx.doi.org/10.1111/j.1538-7836.2006.01893.x PMid:16689760 PMCid:PMC2577223
38. Cal S, Obaya AJ, Llamazares M, Garabaya C, Quesada V, Lopez-Otin C. Cloning, expression analysis, and structural characterization of seven novel human ADAMTSs, a family of metalloproteinases with disintegrin and thrombospondin-1 domains. Gene. 2002; 283: 49-62. http://dx.doi.org/10.1016/S0378-1119(01)00861-7
39. Bork P, Beckmann G. The CUB domain. A widespread module in developmentally regulated proteins. J Mol Biol. 1993; 231: 539-45. http://dx.doi.org/10.1006/jmbi.1993.1305 PMid:8510165
40. Colige A, Sieron AL, Li SW, Schwarze U, Petty E, Wertelecki W, Wilcox W, Krakow D, Cohn DH, Reardon W, Byers PH, Lapiere CM, Prockop DJ, Nusgens BV. Human Ehlers-Danlos syndrome type VII C and bovine dermatosparaxis are caused by mutations in the procollagen I N-proteinase gene. Am J Hum Genet. 1999; 65: 308-17. http://dx.doi.org/10.1086/302504 PMid:10417273 PMCid:PMC1377929
41. Dagoneau N, Benoist-Lasselin C, Huber C, Faivre L, Megarbane A, Alswaid A, Dollfus H, Alembik Y, Munnich A, Legeai-Mallet L, Cormier-Daire V. ADAMTS10 mutations in autosomal recessive Weill-Marchesani syndrome. Am J Hum Genet. 2004; 75: 801-6. http://dx.doi.org/10.1086/425231 PMid:15368195 PMCid:PMC1182109
42. Hurskainen TL, Hirohata S, Seldin MF, Apte SS. ADAM-TS5, ADAM-TS6, and ADAM-TS7, novel members of a new family of zinc metalloproteases. General features and genomic distribution of the ADAM-TS family. J Biol Chem. 1999; 274: 25555-63. http://dx.doi.org/10.1074/jbc.274.36.25555 PMid:10464288
43. Shindo T, Kurihara H, Kuno K, Yokoyama H, Wada T, Kurihara Y, Imai T, Wang Y, Ogata M, Nishimatsu H, Moriyama N, Oh-hashi Y, Morita H, Ishikawa T, Nagai R, Yazaki Y, Matsushima K. ADAMTS-1: a metalloproteinase-disintegrin essential for normal growth, fertility, and organ morphology and function. J Clin Invest. 2000; 105: 1345-52. http://dx.doi.org/10.1172/JCI8635 PMid:10811842 PMCid:PMC315464
44. Tortorella MD, Burn TC, Pratta MA, Abbaszade I, Hollis JM, Liu R, Rosenfeld SA, Copeland RA, Decicco CP, Wynn R, Rockwell A, Yang F, Duke JL, Solomon K, George H, Bruckner R, Nagase H, Itoh Y, Ellis DM, Ross H, Wiswall BH, Murphy K, Hillman MC, Jr., Hollis GF, Newton RC, Magolda RL, Trzaskos JM, Arner EC. Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. Science. 1999; 284: 1664-6. http://dx.doi.org/10.1126/science.284.5420.1664 PMid:10356395
45. Chauhan AK, Kisucka J, Brill A, Walsh MT, Scheiflinger F, Wagner DD. ADAMTS13: a new link between thrombosis and inflammation. J Exp Med. 2008; 205: 2065-74. http://dx.doi.org/10.1084/jem.20080130 PMid:18695007 PMCid:PMC2526201
46. Akiyama M, Takeda S, Kokame K, Takagi J, Miyata T. Crystal structures of the noncatalytic domains of ADAMTS13 reveal multiple discontinuous exosites for von Willebrand factor. Proc Natl Acad Sci U S A. 2009; 106: 19274-9. http://dx.doi.org/10.1073/pnas.0909755106 PMid:19880749 PMCid:PMC2780749
47. Akiyama M, Nakayama D, Takeda S, Kokame K, Takagi J, Miyata T. Crystal structure and enzymatic activity of an ADAMTS13 mutant with the East Asian-specific P475S polymorphism. J Thromb Haemost. 2013. http://dx.doi.org/10.1111/jth.12279 PMid:23621748
48. Bestetti G, Stellari A, Lattuada A, Corbellino M, Parravicini C, Calzarossa C, Cenzuales S, Moroni M, Galli M, Rossi E. ADAMTS 13 genotype and vWF protease activity in an Italian family with TTP. Thromb Haemost. 2003; 90: 955-6. PMid:14597993
49. Zheng X, Nishio K, Majerus EM, Sadler JE. Cleavage of von Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13. J Biol Chem. 2003; 278: 30136-41. http://dx.doi.org/10.1074/jbc. M305331200 PMid:12791682
50. Klaus C, Plaimauer B, Studt JD, Dorner F, Lammle B, Mannucci PM, Scheiflinger F. Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood. 2004; 103: 4514-9. http://dx.doi.org/10.1182/blood-2003-12-4165 PMid:14976043
51. Yiallouros I, Grosse Berkhoff E, Stocker W. The roles of Glu93 and Tyr149 in astacin-like zinc peptidases. FEBS Lett. 2000; 484: 224-8. http://dx.doi.org/10.1016/S0014-5793(00)02163-3
52. Bode W, Fernandez-Catalan C, Tschesche H, Grams F, Nagase H, Maskos K. Structural properties of matrix metalloproteinases. Cell Mol Life Sci. 1999; 55: 639-52. http://dx.doi.org/10.1007/s000180050320 PMid:10357232
53. Bode W, Gomis-Ruth FX, Stockler W. Astacins, serralysins, snake venom and matrix metalloproteinases exhibit identical zinc-binding environments (HEXXHXXGXXH and Met-turn) and topologies and should be grouped into a common family, the 'metzincins'. FEBS Lett. 1993; 331: 134-40. http://dx.doi.org/10.1016/0014-5793(93)80312-I
54. Rawlings ND, Barrett AJ. Evolutionary families of metallopeptidases. Methods Enzymol. 1995; 248: 183-228. http://dx.doi.org/10.1016/0076-6879(95)48015-3
55. Stocker W, Grams F, Baumann U, Reinemer P, Gomis-Ruth FX, McKay DB, Bode W. The metzincins--topological and sequential relations between the astacins, adamalysins, serralysins, and matrixins (collagenases) define a superfamily of zinc-peptidases. Protein Sci. 1995; 4: 823-40. http://dx.doi.org/10.1002/pro.5560040502 PMid:7663339 PMCid:PMC2143131
56. Soejima K, Matsumoto M, Kokame K, Yagi H, Ishizashi H, Maeda H, Nozaki C, Miyata T, Fujimura Y, Nakagaki T. ADAMTS-13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage. Blood. 2003; 102: 3232-7. http://dx.doi.org/10.1182/blood-2003-03-0908 PMid:12869506
57. Ai J, Smith P, Wang S, Zhang P, Zheng XL. The proximal carboxyl-terminal domains of ADAMTS13 determine substrate specificity and are all required for cleavage of von Willebrand factor. J Biol Chem. 2005; 280: 29428-34. http://dx.doi.org/10.1074/jbc. M505513200 PMid:15975930 PMCid:PMC2577221
58. Xiang Y, de Groot R, Crawley JT, Lane DA. Mechanism of von Willebrand factor scissile bond cleavage by a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13). Proc Natl Acad Sci U S A. 2011; 108: 11602-7. http://dx.doi.org/10.1073/pnas.1018559108 PMid:21705658 PMCid:PMC3136259
59. Tsai HM. Shear stress and von Willebrand factor in health and disease. Semin Thromb Hemost. 2003; 29: 479-88. http://dx.doi.org/10.1055/s-2003-44556 PMid:14631548
60. De Cristofaro R, Peyvandi F, Palla R, Lavoretano S, Lombardi R, Merati G, Romitelli F, Di Stasio E, Mannucci PM. Role of chloride ions in modulation of the interaction between von Willebrand factor and ADAMTS-13. J Biol Chem. 2005; 280: 23295-302. http://dx.doi.org/10.1074/jbc. M501143200 PMid:15809291
61. Dong JF, Moake JL, Nolasco L, Bernardo A, Arceneaux W, Shrimpton CN, Schade AJ, McIntire LV, Fujikawa K, Lopez JA. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood. 2002; 100: 4033-9. http://dx.doi.org/10.1182/blood-2002-05-1401 PMid:12393397
62. Dong JF. Cleavage of ultra-large von Willebrand factor by ADAMTS-13 under flow conditions. J Thromb Haemost. 2005; 3: 1710-6. http://dx.doi.org/10.1111/j.1538-7836.2005.01360.x PMid:16102037
63. Auton M, Cruz MA, Moake J. Conformational stability and domain unfolding of the Von Willebrand factor A domains. J Mol Biol. 2007; 366: 986-1000. http://dx.doi.org/10.1016/j.jmb.2006.10.067 PMid:17187823
64. Majerus EM, Anderson PJ, Sadler JE. Binding of ADAMTS13 to von Willebrand factor. J Biol Chem. 2005; 280: 21773-8. http://dx.doi.org/10.1074/jbc. M502529200 PMid:15824096
65. Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002; 347: 589-600. http://dx.doi.org/10.1056/NEJMra020528 PMid:12192020
66. Nishio K, Anderson PJ, Zheng XL, Sadler JE. Binding of platelet glycoprotein Ibalpha to von Willebrand factor domain A1 stimulates the cleavage of the adjacent domain A2 by ADAMTS13. Proc Natl Acad Sci U S A. 2004; 101: 10578-83. http://dx.doi.org/10.1073/pnas.0402041101 PMid:15249683 PMCid:PMC489977
67. Bernardo A, Ball C, Nolasco L, Moake JF, Dong JF. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood. 2004; 104: 100-6. http://dx.doi.org/10.1182/blood-2004-01-0107 PMid:15026315
68. Studt JD, Hovinga JA, Antoine G, Hermann M, Rieger M, Scheiflinger F, Lammle B. Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin. Blood. 2005; 105: 542-4. http://dx.doi.org/10.1182/blood-2004-06-2096 PMid:15367436
69. Raife TJ, Cao W, Atkinson BS, Bedell B, Montgomery RR, Lentz SR, Johnson GF, Zheng XL. Leukocyte proteases cleave von Willebrand factor at or near the ADAMTS13 cleavage site. Blood. 2009; 114: 1666-74. http://dx.doi.org/10.1182/blood-2009-01-195461 PMid:19541819 PMCid:PMC2731642
70. Chen J, Fu X, Wang Y, Ling M, McMullen B, Kulman J, Chung DW, Lopez JA. Oxidative modification of von Willebrand factor by neutrophil oxidants inhibits its cleavage by ADAMTS13. Blood. 2010; 115: 706-12. http://dx.doi.org/10.1182/blood-2009-03-213967 PMid:19812385 PMCid:PMC2810979
71. Lancellotti S, De Filippis V, Pozzi N, Peyvandi F, Palla R, Rocca B, Rutella S, Pitocco D, Mannucci PM, De Cristofaro R. Formation of methionine sulfoxide by peroxynitrite at position 1606 of von Willebrand factor inhibits its cleavage by ADAMTS-13: A new prothrombotic mechanism in diseases associated with oxidative stress. Free Radic Biol Med. 2010; 48: 446-56. http://dx.doi.org/10.1016/j.freeradbiomed.2009.11.020 PMid:19969076
72. Lancellotti S, De Filippis V, Pozzi N, Oggianu L, Rutella S, Scaglione GL, Maset F, Peyvandi F, Mannucci PM, De Cristofaro R. Oxidized von Willebrand factor is efficiently cleaved by serine proteases from primary granules of leukocytes: divergence from ADAMTS-13. J Thromb Haemost. 2011; 9: 1620-7. http://dx.doi.org/10.1111/j.1538-7836.2011.04367.x PMid:21605335
73. Wohner N, Kovacs A, Machovich R, Kolev K. Modulation of the von Willebrand factor-dependent platelet adhesion through alternative proteolytic pathways. Thromb Res. 2012; 129: e41-6. http://dx.doi.org/10.1016/j.thromres.2011.11.021 PMid:22178067 PMCid:PMC3323834
74. George JN. Clinical practice. Thrombotic thrombocytopenic purpura. N Engl J Med. 2006; 354: 1927-35. http://dx.doi.org/10.1056/NEJMcp053024 PMid:16672704
75. Silverstein A. Thrombotic thrombocytopenic purpura. The initial neurologic manifestations. Arch Neurol. 1968; 18: 358-62. http://dx.doi.org/10.1001/archneur.1968.00470340044003 PMid:5689024
76. Ruggenenti P, Remuzzi G. Thrombotic microangiopathies. Crit Rev Oncol Hematol. 1991; 11: 243-65. http://dx.doi.org/10.1016/1040-8428(91)90028-B
77. McLeod BC. Thrombotic microangiopathies in bone marrow and organ transplant patients. J Clin Apher. 2002; 17: 118-23. http://dx.doi.org/10.1002/jca.10030 PMid:12378546
78. Asada Y, Sumiyoshi A, Hayashi T, Suzumiya J, Kaketani K. Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen. Thromb Res. 1985; 38: 469-79. http://dx.doi.org/10.1016/0049-3848(85)90180-X
79. Tsai HM, Chandler WL, Sarode R, Hoffman R, Jelacic S, Habeeb RL, Watkins SL, Wong CS, Williams GD, Tarr PI. von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli O157:H7-associated hemolytic uremic syndrome. Pediatr Res. 2001; 49: 653-9. http://dx.doi.org/10.1203/00006450-200105000-00008 PMid:11328948
80. Hosler GA, Cusumano AM, Hutchins GM. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases. Arch Pathol Lab Med. 2003; 127: 834-9. PMid:12823037
81. Camilleri RS, Cohen H, Mackie IJ, Scully M, Starke RD, Crawley JT, Lane DA, Machin SJ. Prevalence of the ADAMTS-13 missense mutation R1060W in late onset adult thrombotic thrombocytopenic purpura. J Thromb Haemost. 2008; 6: 331-8. PMid:18031293
82. Veyradier A, Lavergne JM, Ribba AS, Obert B, Loirat C, Meyer D, Girma JP. Ten candidate ADAMTS13 mutations in six French families with congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome). J Thromb Haemost. 2004; 2: 424-9. http://dx.doi.org/10.1111/j.1538-7933.2004.00623.x PMid:15009458
83. Kentouche K, Budde U, Furlan M, Scharfe V, Schneppenheim R, Zintl F. Remission of thrombotic thrombocytopenic purpura in a patient with compound heterozygous deficiency of von Willebrand factor-cleaving protease by infusion of solvent/detergent plasma. Acta Paediatr. 2002; 91: 1056-9. http://dx.doi.org/10.1111/j.1651-2227.2002.tb00099.x PMid:12434890
84. Antoine G, Zimmermann K, Plaimauer B, Grillowitzer M, Studt JD, Lammle B, Scheiflinger F. ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factor-cleaving protease activity by recombinant human ADAMTS13. Br J Haematol. 2003; 120: 821-4. http://dx.doi.org/10.1046/j.1365-2141.2003.04183.x PMid:12614216
85. Assink K, Schiphorst R, Allford S, Karpman D, Etzioni A, Brichard B, van de Kar N, Monnens L, van den Heuvel L. Mutation analysis and clinical implications of von Willebrand factor-cleaving protease deficiency. Kidney Int. 2003; 63: 1995-9. http://dx.doi.org/10.1046/j.1523-1755.63.6s.1.x PMid:12753286
86. Schneppenheim R, Budde U, Oyen F, Angerhaus D, Aumann V, Drewke E, Hassenpflug W, Haberle J, Kentouche K, Kohne E, Kurnik K, Mueller-Wiefel D, Obser T, Santer R, Sykora KW. von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP. Blood. 2003; 101: 1845-50. http://dx.doi.org/10.1182/blood-2002-08-2399 PMid:12393505
87. Schneppenheim R, Kremer Hovinga JA, Becker T, Budde U, Karpman D, Brockhaus W, Hrachovinova I, Korczowski B, Oyen F, Rittich S, von Rosen J, Tjonnfjord GE, Pimanda JE, Wienker TF, Lammle B. A common origin of the 4143insA ADAMTS13 mutation. Thromb Haemost. 2006; 96: 3-6. PMid:16807643
88. Savasan S, Lee SK, Ginsburg D, Tsai HM. ADAMTS13 gene mutation in congenital thrombotic thrombocytopenic purpura with previously reported normal VWF cleaving protease activity. Blood. 2003; 101: 4449-51. http://dx.doi.org/10.1182/blood-2002-12-3796 PMid:12576319
89. Matsumoto M, Kokame K, Soejima K, Miura M, Hayashi S, Fujii Y, Iwai A, Ito E, Tsuji Y, Takeda-Shitaka M, Iwadate M, Umeyama H, Yagi H, Ishizashi H, Banno F, Nakagaki T, Miyata T, Fujimura Y. Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw-Schulman syndrome. Blood. 2004; 103: 1305-10. http://dx.doi.org/10.1182/blood-2003-06-1796 PMid:14563640
90. Pimanda JE, Maekawa A, Wind T, Paxton J, Chesterman CN, Hogg PJ. Congenital thrombotic thrombocytopenic purpura in association with a mutation in the second CUB domain of ADAMTS13. Blood. 2004; 103: 627-9. http://dx.doi.org/10.1182/blood-2003-04-1346 PMid:14512317
91. Uchida T, Wada H, Mizutani M, Iwashita M, Ishihara H, Shibano T, Suzuki M, Matsubara Y, Soejima K, Matsumoto M, Fujimura Y, Ikeda Y, Murata M. Identification of novel mutations in ADAMTS13 in an adult patient with congenital thrombotic thrombocytopenic purpura. Blood. 2004; 104: 2081-3. http://dx.doi.org/10.1182/blood-2004-02-0715 PMid:15126318
92. Licht C, Stapenhorst L, Simon T, Budde U, Schneppenheim R, Hoppe B. Two novel ADAMTS13 gene mutations in thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome (TTP/HUS). Kidney Int. 2004; 66: 955-8. http://dx.doi.org/10.1111/j.1523-1755.2004.00841.x PMid:15327386
93. Snider CE, Moore JC, Warkentin TE, Finch CN, Hayward CP, Kelton JG. Dissociation between the level of von Willebrand factor-cleaving protease activity and disease in a patient with congenital thrombotic thrombocytopenic purpura. Am J Hematol. 2004; 77: 387-90. http://dx.doi.org/10.1002/ajh.20221 PMid:15551280
94. Noris M, Bucchioni S, Galbusera M, Donadelli R, Bresin E, Castelletti F, Caprioli J, Brioschi S, Scheiflinger F, Remuzzi G. Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement. J Am Soc Nephrol. 2005; 16: 1177-83. http://dx.doi.org/10.1681/ASN.2005010086 PMid:15800115
95. Liu F, Jin J, Dong NZ, Wang YG, Ruan CG. [Identification of two novel mutations in ADAMTS13 gene in a patient with hereditary thrombotic thrombocytopenic purpura]. Zhonghua Xue Ye Xue Za Zhi. 2005; 26: 521-4. PMid:16468327
96. Donadelli R, Banterla F, Galbusera M, Capoferri C, Bucchioni S, Gastoldi S, Nosari S, Monteferrante G, Ruggeri ZM, Bresin E, Scheiflinger F, Rossi E, Martinez C, Coppo R, Remuzzi G, Noris M. In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura. Thromb Haemost. 2006; 96: 454-64. PMid:17003922
97. Palla R, Lavoretano S, Lombardi R, Garagiola I, Karimi M, Afrasiabi A, Ramzi M, De Cristofaro R, Peyvandi F. The first deletion mutation in the TSP1-6 repeat domain of ADAMTS13 in a family with inherited thrombotic thrombocytopenic purpura. Haematologica. 2009; 94: 289-93. http://dx.doi.org/10.3324/haematol.13524 PMid:19116307 PMCid:PMC2635406
98. Plaimauer B, Fuhrmann J, Mohr G, Wernhart W, Bruno K, Ferrari S, Konetschny C, Antoine G, Rieger M, Scheiflinger F. Modulation of ADAMTS13 secretion and specific activity by a combination of common amino acid polymorphisms and a missense mutation. Blood. 2006; 107: 118-25. http://dx.doi.org/10.1182/blood-2005-06-2482 PMid:16160007
99. Shibagaki Y, Matsumoto M, Kokame K, Ohba S, Miyata T, Fujimura Y, Fujita T. Novel compound heterozygote mutations (H234Q/R1206X) of the ADAMTS13 gene in an adult patient with Upshaw-Schulman syndrome showing predominant episodes of repeated acute renal failure. Nephrol Dial Transplant. 2006; 21: 1289-92. http://dx.doi.org/10.1093/ndt/gfk072 PMid:16449289
100. Tao Z, Anthony K, Peng Y, Choi H, Nolasco L, Rice L, Moake JL, Dong JF. Novel ADAMTS-13 mutations in an adult with delayed onset thrombotic thrombocytopenic purpura. J Thromb Haemost. 2006; 4: 1931-5. http://dx.doi.org/10.1111/j.1538-7836.2006.02098.x PMid:16796708
101. Hommais A, Rayes J, Houllier A, Obert B, Legendre P, Veyradier A, Girma JP, Ribba AS. Molecular characterization of four ADAMTS13 mutations responsible for congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome). Thromb Haemost. 2007; 98: 593-9. PMid:17849048
102. Meyer SC, Jeddi R, Meddeb B, Gouider E, Lammle B, Kremer Hovinga JA. A first case of congenital TTP on the African continent due to a new homozygous mutation in the catalytic domain of ADAMTS13. Ann Hematol. 2008; 87: 663-6. http://dx.doi.org/10.1007/s00277-008-0496-6 PMid:18443791
103. Kokame K, Aoyama Y, Matsumoto M, Fujimura Y, Miyata T. Inherited and de novo mutations of ADAMTS13 in a patient with Upshaw-Schulman syndrome. J Thromb Haemost. 2008; 6: 213-5. http://dx.doi.org/10.1111/j.1538-7836.2007.02828.x PMid:17988227
104. Garagiola I, Valsecchi C, Lavoretano S, Oren H, Bohm M, Peyvandi F. Nonsense-mediated mRNA decay in the ADAMTS13 gene caused by a 29-nucleotide deletion. Haematologica. 2008; 93: 1678-85. http://dx.doi.org/10.3324/haematol.13102 PMid:18835837
105. Fujimura Y, Matsumoto M, Kokame K, Isonishi A, Soejima K, Akiyama N, Tomiyama J, Natori K, Kuranishi Y, Imamura Y, Inoue N, Higasa S, Seike M, Kozuka T, Hara M, Wada H, Murata M, Ikeda Y, Miyata T, George JN. Pregnancy-induced thrombocytopenia and TTP, and the risk of fetal death, in Upshaw-Schulman syndrome: a series of 15 pregnancies in 9 genotyped patients. Br J Haematol. 2009; 144: 742-54. http://dx.doi.org/10.1111/j.1365-2141.2008.07515.x PMid:19055667
106. Manea M, Kristoffersson A, Tsai HM, Zhou W, Winqvist I, Oldaeus G, Billstrom R, Bjork P, Holmberg L, Karpman D. ADAMTS13 phenotype in plasma from normal individuals and patients with thrombotic thrombocytopenic purpura. Eur J Pediatr. 2007; 166: 249-57. http://dx.doi.org/10.1007/s00431-006-0354-2 PMid:17187257 PMCid:PMC1820762
107. Motto DG, Chauhan AK, Zhu G, Homeister J, Lamb CB, Desch KC, Zhang W, Tsai HM, Wagner DD, Ginsburg D. Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest. 2005; 115: 2752-61. http://dx.doi.org/10.1172/JCI26007 PMid:16200209 PMCid:PMC1240119
108. Banno F, Kokame K, Okuda T, Honda S, Miyata S, Kato H, Tomiyama Y, Miyata T. Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura. Blood. 2006; 107: 3161-6. http://dx.doi.org/10.1182/blood-2005-07-2765 PMid:16368888
109. Nolasco LH, Turner NA, Bernardo A, Tao Z, Cleary TG, Dong JF, Moake JL. Hemolytic uremic syndrome-associated Shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers. Blood. 2005; 106: 4199-209. http://dx.doi.org/10.1182/blood-2005-05-2111 PMid:16131569 PMCid:PMC1895236
110. Tao Z, Peng Y, Nolasco L, Cal S, Lopez-Otin C, Li R, Moake JL, Lopez JA, Dong JF. Recombinant CUB-1 domain polypeptide inhibits the cleavage of ULVWF strings by ADAMTS13 under flow conditions. Blood. 2005; 106: 4139-45. http://dx.doi.org/10.1182/blood-2005-05-2029 PMid:16141351 PMCid:PMC1895231
111. Tsai HM. Pathophysiology of thrombotic thrombocytopenic purpura. Int J Hematol. 91: 1-19. http://dx.doi.org/10.1007/s12185-009-0476-1 PMid:20058209 PMCid:PMC3159000
112. Jang MJ, Kim NK, Chong SY, Kim HJ, Lee SJ, Kang MS, Oh D. Frequency of Pro475Ser polymorphism of ADAMTS13 gene and its association with ADAMTS-13 activity in the Korean population. Yonsei Med J. 2008; 49: 405-8. http://dx.doi.org/10.3349/ymj.2008.49.3.405 PMid:18581589 PMCid:PMC2615352
113. Akiyama M, Kokame K, Miyata T. ADAMTS13 P475S polymorphism causes a lowered enzymatic activity and urea lability in vitro. J Thromb Haemost. 2008; 6: 1830-2. http://dx.doi.org/10.1111/j.1538-7836.2008.03109.x PMid:18665921
114. Borgi A, Khemiri M, Veyradier A, Kazdaghli K, Barsaoui S. Congenital Thrombotic Thrombocytopenic Purpura: Atypical Presentation and New ADAMTS 13 Mutation in a Tunisian Child. Mediterr J Hematol Infect Dis. 2013; 5: e2013041. http://dx.doi.org/10.4084/mjhid.2013.041 PMid:23795279 PMCid:PMC3684349
115. Sadler JE, Moake JL, Miyata T, George JN. Recent advances in thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program. 2004: 407-23. http://dx.doi.org/10.1182/asheducation-2004.1.407 PMid:15561695
116. Veyradier A, Obert B, Houllier A, Meyer D, Girma JP. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood. 2001; 98: 1765-72. http://dx.doi.org/10.1182/blood. V98.6.1765 PMid:11535510
117. Coppo P, Bengoufa D, Veyradier A, Wolf M, Bussel A, Millot GA, Malot S, Heshmati F, Mira JP, Boulanger E, Galicier L, Durey-Dragon MA, Fremeaux-Bacchi V, Ramakers M, Pruna A, Bordessoule D, Gouilleux V, Scrobohaci ML, Vernant JP, Moreau D, Azoulay E, Schlemmer B, Guillevin L, Lassoued K. Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine (Baltimore). 2004; 83: 233-44. http://dx.doi.org/10.1097/01.md.0000133622.03370.07
118. Zheng XL, Kaufman RM, Goodnough LT, Sadler JE. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood. 2004; 103: 4043-9. http://dx.doi.org/10.1182/blood-2003-11-4035 PMid:14982878
119. Rieger M, Mannucci PM, Kremer Hovinga JA, Herzog A, Gerstenbauer G, Konetschny C, Zimmermann K, Scharrer I, Peyvandi F, Galbusera M, Remuzzi G, Bohm M, Plaimauer B, Lammle B, Scheiflinger F. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood. 2005; 106: 1262-7. http://dx.doi.org/10.1182/blood-2004-11-4490 PMid:15890682
120. Mannucci PM. Thrombotic thromboytopenic purpura: another example of immunomediated thrombosis. Pathophysiol Haemost Thromb. 2006; 35: 89-97. http://dx.doi.org/10.1159/000093549 PMid:16855352
121. Mannucci PM, Bohm M, Scharrer I, Scheiflinger F. Patterns of changes of anti-ADAMTS13 after plasma exchange. J Thromb Haemost. 2006; 4: 1405-6. http://dx.doi.org/10.1111/j.1538-7836.2006.01960.x PMid:16706988
122. Waters B, Qadura M, Burnett E, Chegeni R, Labelle A, Thompson P, Hough C, Lillicrap D. Anti-CD3 prevents factor VIII inhibitor development in hemophilia A mice by a regulatory CD4+CD25+-dependent mechanism and by shifting cytokine production to favor a Th1 response. Blood. 2009; 113: 193-203. http://dx.doi.org/10.1182/blood-2008-04-151597 PMid:18815284
123. Terrell DR, Williams LA, Vesely SK, Lammle B, Hovinga JA, George JN. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost. 2005; 3: 1432-6. http://dx.doi.org/10.1111/j.1538-7836.2005.01436.x PMid:15978100
124. Ferrari S, Mudde GC, Rieger M, Veyradier A, Kremer Hovinga JA, Scheiflinger F. IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost. 2009; 7: 1703-10. http://dx.doi.org/10.1111/j.1538-7836.2009.03568.x PMid:19682238
125. Dong L, Chandrasekaran V, Zhou W, Tsai HM. Evolution of ADAMTS13 antibodies in a fatal case of thrombotic thrombocytopenic purpura. Am J Hematol. 2008; 83: 815-7. http://dx.doi.org/10.1002/ajh.21217 PMid:18661493 PMCid:PMC2574606
126. Zhou W, Dong L, Ginsburg D, Bouhassira EE, Tsai HM. Enzymatically active ADAMTS13 variants are not inhibited by anti-ADAMTS13 autoantibodies: a novel therapeutic strategy? J Biol Chem. 2005; 280: 39934-41. http://dx.doi.org/10.1074/jbc. M504919200 PMid:16203734 PMCid:PMC2582217
127. Tsai HM, Li A, Rock G. Inhibitors of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura. Clin Lab. 2001; 47: 387-92. PMid:11499801
128. Favaloro EJ, Bonar R, Kershaw G, Duncan E, Sioufi J, Marsden K. Investigations from external quality assurance programs reveal a high degree of variation in the laboratory identification of coagulation factor inhibitors. Semin Thromb Hemost. 2009; 35: 794-805. http://dx.doi.org/10.1055/s-0029-1245112 PMid:20169516
129. Yomtovian R, Niklinski W, Silver B, Sarode R, Tsai HM. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature. Br J Haematol. 2004; 124: 787-95. http://dx.doi.org/10.1111/j.1365-2141.2004.04836.x PMid:15009067 PMCid:PMC3153075
130. Saito I, Folsom AR, Brancati FL, Duncan BB, Chambless LE, McGovern PG. Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Ann Intern Med. 2000; 133: 81-91. http://dx.doi.org/10.7326/0003-4819-133-2-200007180-00007 PMid:10896647
131. Spiel AO, Gilbert JC, Jilma B. von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation. 2008; 117: 1449-59. http://dx.doi.org/10.1161/CIRCULATIONAHA.107.722827 PMid:18347221
132. Frankel DS, Meigs JB, Massaro JM, Wilson PW, O'Donnell CJ, D'Agostino RB, Tofler GH. Von Willebrand factor, type 2 diabetes mellitus, and risk of cardiovascular disease: the framingham offspring study. Circulation. 2008; 118: 2533-9. http://dx.doi.org/10.1161/CIRCULATIONAHA.108.792986 PMid:19029465 PMCid:PMC2746947
133. Hanson E, Jood K, Karlsson S, Nilsson S, Blomstrand C, Jern C. Plasma levels of von Willebrand factor in the etiologic subtypes of ischemic stroke. J Thromb Haemost. 2011; 9: 275-81. http://dx.doi.org/10.1111/j.1538-7836.2010.04134.x PMid:21054779
134. Wieberdink RG, van Schie MC, Koudstaal PJ, Hofman A, Witteman JC, de Maat MP, Leebeek FW, Breteler MM. High von Willebrand factor levels increase the risk of stroke: the Rotterdam study. Stroke. 2010; 41: 2151-6. http://dx.doi.org/10.1161/STROKEAHA.110.586289 PMid:20798373
135. Oggianu L, Lancellotti S, Pitocco D, Zaccardi F, Rizzo P, Martini F, Ghirlanda G, De Cristofaro R. The oxidative modification of von Willebrand factor is associated with thrombotic angiopathies in diabetes mellitus. PLoS One. 2013; 8: e55396. http://dx.doi.org/10.1371/journal.pone.0055396 PMid:23383177 PMCid:PMC3561310
136. De Filippis V, Lancellotti S, Maset F, Spolaore B, Pozzi N, Gambaro G, Oggianu L, Calo LA, De Cristofaro R. Oxidation of Met1606 in von Willebrand factor is a risk factor for thrombotic and septic complications in chronic renal failure. Biochem J. 2012; 442: 423-32. http://dx.doi.org/10.1042/BJ20111798 PMid:22091998
137. Wada H, Kaneko T, Ohiwa M, Tanigawa M, Tamaki S, Minami N, Takahashi H, Deguchi K, Nakano T, Shirakawa S. Plasma cytokine levels in thrombotic thrombocytopenic purpura. Am J Hematol. 1992; 40: 167-70. http://dx.doi.org/10.1002/ajh.283040030 3 PMid:1609769